Verteporfin Clinical Trials (2026): 46 Studies for Macular Degeneration & Choroidal Neovascularization
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
46 Verteporfin clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 30 indications (including Macular Degeneration & Choroidal Neovascularization) and 3,386 total planned enrollment. 8 Phase 3 Verteporfin trials and 13 Phase 2, 6 Phase 4 are listed. 8 Verteporfin clinical trials are actively recruiting at 6 U.S. sites across 4 states. Most recent activity: NCT06381154 (Dec 2029).
Where to Participate: All Verteporfin Trial Sites in the U.S. (6 sites across 4 states)
Every actively recruiting Verteporfintrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT04590664 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06381154 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06306638 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT03067051 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06807359 | Map |
| PA | Abramson Cancer Center | Philadelphia19104 | NCT06306638 | Map |
Verteporfin clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | terminated | withdrawn | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|
| P1 | 1 | 1 | 2 | ||||
| P1/P2 | 4 | 3 | 1 | 8 | |||
| P2 | 1 | 8 | 1 | 1 | 2 | 13 | |
| P2/P3 | 1 | 1 | |||||
| P3 | 5 | 1 | 1 | 1 | 8 | ||
| P4 | 4 | 1 | 1 | 6 | |||
| N/A | 1 | 3 | 1 | 2 | 1 | 8 |
Recruiting Verteporfin clinical trials (8)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06381154 | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer | P2 | Locally Advanced Pancreatic Adenocarcinoma | 25 | Dec 2024 |
| NCT06306638 | Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction | P1/P2 | Malignant Solid Neoplasm | 42 | Oct 2024 |
| NCT06807359 | Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System | P1/P2 | Prostate Cancer | 43 | Jan 2025 |
| NCT07488988 | SCARFREE-001SCARFREE-001: Verteporfin for Scar Prevention | P2 | Surgical Scar | 12 | Jun 2026 |
| NCT03067051 | Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System | P1/P2 | Recurrent Prostate Cancer | 66 | Mar 2017 |
| NCT06944249 | Effect of YAP1-inhibition in Surgical Wounds. | P1/P2 | Scar Formation | 24 | May 2025 |
| NCT05589974 | Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy | — | Central Serous Chorioretinopathy | 50 | Oct 2022 |
| NCT04590664 | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | P1/P2 | Glioblastoma | 24 | Jan 2021 |
Verteporfin clinical trials by indication
Macular Degeneration (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01746875 | — | N/A | terminated | A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes |
| NCT00527475 | RAP | P2 | completed | Ranibizumab and Reduced Fluence PDT for AMD |
| NCT00436553 | — | P3 | completed | Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization |
| NCT00433017 | AMD | P2/P3 | terminated | Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) |
| NCT00359164 | PDT | P2 | completed | Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab. |
| NCT00242580 | VERITAS | P3 | completed | A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib |
Choroidal Neovascularization (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01256580 | CNV | N/A | withdrawn | Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD |
| NCT00570193 | PBS | P1/P2 | completed | Photodynamic and Pharmacologic Treatment of CNV |
| NCT00492284 | RADICAL | P2 | completed | Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) |
| NCT00426998 | — | P2 | completed | Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD |
Polypoidal Choroidal Vasculopathy (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03459144 | — | N/A | completed | Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen |
| NCT01360151 | — | N/A | unknown | Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy |
| NCT00674323 | PCV | P4 | completed | Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy |
Central Serous Chorioretinopathy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05589974 | — | N/A | recruiting | Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy |
| NCT01019668 | — | N/A | completed | Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy |
Neovascular Age-related Macular Degeneration (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02457026 | — | N/A | withdrawn | Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD |
| NCT00696592 | ARMAST | P2 | withdrawn | Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration |
Age-related Macular Degeneration (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01846273 | EVEREST II | P4 | completed | Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) |
| NCT00390026 | — | P3 | withdrawn | The Avastin vs Visudyne for Neovascular AMD Study |
Chronic Central Serous Chorioretinopathy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01325181 | — | P1/P2 | completed | Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy |
| NCT00211445 | CSC | P2 | completed | Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) |
Age Related Macular Degeneration (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01570608 | — | P3 | completed | Lucentis KAV Study |
| NCT00390208 | PDEX | P2 | completed | Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration |
Age-Related Macular Degeneration (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00134667 | AMD | P4 | terminated | Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD) |
| NCT00135837 | POOL | P4 | completed | Photodynamic Therapy in Occult-Only Lesions (POOL) |
Surgical Scar (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07488988 | SCARFREE-001 | P2 | not yet recruiting | SCARFREE-001: Verteporfin for Scar Prevention |
Scar Formation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06944249 | — | P1/P2 | not yet recruiting | Effect of YAP1-inhibition in Surgical Wounds. |
Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06807359 | — | P1/P2 | recruiting | Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System |
Locally Advanced Pancreatic Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06381154 | — | P2 | recruiting | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer |
Malignant Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06306638 | — | P1/P2 | recruiting | Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction |
Exudative Age Related Macular Degeneration (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04075136 | OCTA | P4 | withdrawn | Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy |
Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04590664 | — | P1/P2 | recruiting | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma |
Advanced Pancreatic Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03033225 | — | P2 | completed | Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study |
Recurrent Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03067051 | — | P1/P2 | recruiting | Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System |
Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02939274 | CLIPT | P2 | unknown | An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer |
Pleural Effusion, Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02702700 | PDT-lipo | P1 | terminated | Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies |
Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01922102 | Brilliance | P3 | completed | Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia |
Breast Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02872064 | — | N/A | completed | Treatment of Primary Breast Cancer Using PDT |
Pathological Myopia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01217944 | — | P3 | completed | Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia |
Neovascular Age Related Macular Degeneration (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00574093 | Luvi | P2 | completed | Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD |
Presumed Ocular Histoplasmosis (POHS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00546936 | — | P2 | unknown | Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis |
Age-Related Maculopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00473642 | PDT | P4 | completed | Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration |
Neovascular Age-Related Macular Degeneration (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00370539 | — | P3 | unknown | Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD |
Melanoma (Skin) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00007969 | — | P1/P2 | completed | Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma |
Brain and Central Nervous System Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00002647 | — | P1 | unknown | Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors |
Basal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00049959 | — | P3 | terminated | Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin. |
Verteporfin pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| OCTA | NCT04075136 | P4 | withdrawn | Exudative Age Related Macular Degeneration | 0 | — |
| EVEREST II | NCT01846273 | P4 | completed | Age-related Macular Degeneration | 321 | PMID 40504425 |
| PDT | NCT00473642 | P4 | completed | Age-Related Maculopathy | 31 | — |
| AMD | NCT00134667 | P4 | terminated | Age-Related Macular Degeneration | 360 | — |
| PCV | NCT00674323 | P4 | completed | Polypoidal Choroidal Vasculopathy | 61 | PMID 25758601 |
| POOL | NCT00135837 | P4 | completed | Age-Related Macular Degeneration | 202 | — |
| Brilliance | NCT01922102 | P3 | completed | Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM) | 457 | — |
| VERITAS | NCT00242580 | P3 | completed | Macular Degeneration | 111 | — |
| SCARFREE-001 | NCT07488988 | P2 | not yet recruiting | Surgical Scar | 12 | PMID 23918388 |
| CLIPT | NCT02939274 | P2 | unknown | Metastatic Breast Cancer | 15 | — |
| RADICAL | NCT00492284 | P2 | completed | Choroidal Neovascularization | 162 | — |
| RAP | NCT00527475 | P2 | completed | Macular Degeneration | 60 | — |
| PDEX | NCT00390208 | P2 | completed | Age Related Macular Degeneration | 60 | PMID 11381074 |
| Luvi | NCT00574093 | P2 | completed | Neovascular Age Related Macular Degeneration | 15 | — |
| PDT | NCT00359164 | P2 | completed | Macular Degeneration | 36 | — |
| ARMAST | NCT00696592 | P2 | withdrawn | Neovascular Age-related Macular Degeneration | 0 | — |
| CSC | NCT00211445 | P2 | completed | Chronic Central Serous Chorioretinopathy | 11 | — |
Terminated and withdrawn Verteporfin trials (10)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04075136withdrawnOptical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
- NCT02702700terminatedPhoto-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies
- NCT02457026withdrawnAdjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
- NCT01746875terminatedA Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes
- NCT01256580withdrawnIntravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
- NCT00433017terminatedVerteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
- NCT00390026withdrawnThe Avastin vs Visudyne for Neovascular AMD Study
- NCT00134667terminatedMacugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
- NCT00696592withdrawnPhotodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration
- NCT00049959terminatedTwo Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.
All Verteporfin trials (46)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06381154 | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer | P2 | recruiting | 25 | Mayo Clinic | Dec 2024 | |
| NCT06306638 | Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction | P1/P2 | recruiting | 42 | Roswell Park Cancer Institute | Oct 2024 | |
| NCT06807359 | Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System | P1/P2 | recruiting | 43 | SpectraCure AB | Jan 2025 | |
| NCT07488988 | SCARFREE-001 | SCARFREE-001: Verteporfin for Scar Prevention | P2 | not yet recruiting | 12 | Odense University Hospital | Jun 2026 |
| NCT03067051 | Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System | P1/P2 | recruiting | 66 | SpectraCure AB | Mar 2017 | |
| NCT06944249 | Effect of YAP1-inhibition in Surgical Wounds. | P1/P2 | not yet recruiting | 24 | Jöri Pünchera | May 2025 | |
| NCT05589974 | Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy | — | recruiting | 50 | Helse Stavanger HF | Oct 2022 | |
| NCT04590664 | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | P1/P2 | recruiting | 24 | Emory University | Jan 2021 | |
| NCT04075136 | OCTA | Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy | P4 | withdrawn | 0 | Wake Forest University Health Sciences | Mar 2023 |
| NCT03033225 | Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study | P2 | completed | 13 | Mayo Clinic | May 2017 | |
| NCT02939274 | CLIPT | An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer | P2 | unknown | 15 | Rogers Sciences Inc. | Oct 2016 |
| NCT02702700 | PDT-lipo | Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies | P1 | terminated | 1 | Centre Hospitalier Universitaire Vaudois | Jan 2016 |
| NCT02457026 | Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD | N/A | withdrawn | 0 | Duke University | Jan 2016 | |
| NCT02872064 | Treatment of Primary Breast Cancer Using PDT | N/A | completed | 12 | University College, London | Jan 2013 | |
| NCT01846273 | EVEREST II | Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) | P4 | completed | 321 | Novartis Pharmaceuticals | Aug 2013 |
| NCT01922102 | Brilliance | Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia | P3 | completed | 457 | Novartis Pharmaceuticals | Sep 2013 |
| NCT01746875 | A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes | N/A | terminated | 9 | Norwegian University of Science and Technology | Feb 2014 | |
| NCT03459144 | Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen | N/A | completed | 60 | Sun Yat-sen University | Dec 2012 | |
| NCT01256580 | CNV | Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD | N/A | withdrawn | 0 | Massachusetts Eye and Ear Infirmary | Aug 2010 |
| NCT01325181 | Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy | P1/P2 | completed | 34 | Jang Won Heo | Jul 2009 | |
| NCT01217944 | Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia | P3 | completed | 277 | Novartis Pharmaceuticals | Oct 2010 | |
| NCT01570608 | Lucentis KAV Study | P3 | completed | 51 | The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery | Mar 2007 | |
| NCT01019668 | Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy | N/A | completed | 24 | Shin Kong Wu Ho-Su Memorial Hospital | Nov 2008 | |
| NCT00570193 | PBS | Photodynamic and Pharmacologic Treatment of CNV | P1/P2 | completed | 41 | Mid-Atlantic Retina Consultations, Inc. | Dec 2006 |
| NCT01360151 | Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy | N/A | unknown | 16 | Seoul St. Mary's Hospital | Feb 2011 | |
| NCT00492284 | RADICAL | Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) | P2 | completed | 162 | QLT Inc. | Jul 2007 |
| NCT00546936 | Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis | P2 | unknown | 30 | Barnes Retina Institute | Oct 2007 | |
| NCT00473642 | PDT | Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration | P4 | completed | 31 | Oklahoma State University Center for Health Sciences | May 2007 |
| NCT00527475 | RAP | Ranibizumab and Reduced Fluence PDT for AMD | P2 | completed | 60 | Texas Retina Associates | May 2007 |
| NCT00390208 | PDEX | Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration | P2 | completed | 60 | Bay Area Retina Associates | Aug 2006 |
| NCT00574093 | Luvi | Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD | P2 | completed | 15 | Fondazione G.B. Bietti, IRCCS | Jan 2008 |
| NCT00436553 | Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization | P3 | completed | 321 | Novartis | Feb 2007 | |
| NCT00433017 | AMD | Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) | P2/P3 | terminated | 255 | Novartis | May 2007 |
| NCT00390026 | The Avastin vs Visudyne for Neovascular AMD Study | P3 | withdrawn | 0 | St. Erik Eye Hospital | Nov 2006 | |
| NCT00134667 | AMD | Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD) | P4 | terminated | 360 | Eyetech Pharmaceuticals | Mar 2005 |
| NCT00359164 | PDT | Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab. | P2 | completed | 36 | University of British Columbia | Jul 2006 |
| NCT00674323 | PCV | Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy | P4 | completed | 61 | Novartis | Apr 2008 |
| NCT00696592 | ARMAST | Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration | P2 | withdrawn | 0 | University of Padova | Jan 2007 |
| NCT00370539 | Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD | P3 | unknown | 0 | Shahid Beheshti University of Medical Sciences | Sep 2006 | |
| NCT00426998 | Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD | P2 | completed | 30 | Retinal Consultants Medical Group | Apr 2006 | |
| NCT00211445 | CSC | Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) | P2 | completed | 11 | Manhattan Eye, Ear & Throat Hospital | Jul 2002 |
| NCT00242580 | VERITAS | A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib | P3 | completed | 111 | Novartis Pharmaceuticals | Sep 2005 |
| NCT00049959 | Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin. | P3 | terminated | 0 | QLT Inc. | — | |
| NCT00135837 | POOL | Photodynamic Therapy in Occult-Only Lesions (POOL) | P4 | completed | 202 | Novartis | Jun 2003 |
| NCT00007969 | Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma | P1/P2 | completed | 0 | QLT Inc. | Oct 2000 | |
| NCT00002647 | Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors | P1 | unknown | 24 | Medical College of Wisconsin | May 1994 |
Verteporfin clinical trials: frequently asked questions
- How many Verteporfin clinical trials are there?
- 46 Verteporfin clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants. 23 are marked completed.
- Are Verteporfin clinical trials recruiting in 2026?
- Yes — 6 Verteporfin trials are actively recruiting in 2026, with 6 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Verteporfin being studied for?
- Verteporfin is being studied for Macular Degeneration, Choroidal Neovascularization, Polypoidal Choroidal Vasculopathy, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 and 46 more. The trials are grouped by indication on this page.
- What phase is Verteporfin in?
- Verteporfin clinical trials span 6 Phase 4, 8 Phase 3, 13 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Verteporfin clinical trials?
- The lead sponsor across the most Verteporfin trials is Novartis, with 35 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Verteporfinas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: